Windtree Therapeutics
Cardiovascular/critical-care therapeutics -- istaroxime program now operated via subsidiary Seismic Pharmaceuticals Operations LLC
WINT · OTC · United States
Share price · WINT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when WINT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 31 Jul 2026+100.0%
Nothing announced by WINT that day or the session before.
- 27 Jul 2026+100.0%
Nothing announced by WINT that day or the session before.
- 24 Jul 2026-99.0%
Nothing announced by WINT that day or the session before.
- 8 Jul 2026+100.0%
Nothing announced by WINT that day or the session before.
- 2 Jul 2026+100.0%
Nothing announced by WINT that day or the session before.
- 29 Jun 2026+100.0%
Nothing announced by WINT that day or the session before.
- 18 Jun 2026+100.0%
Nothing announced by WINT that day or the session before.
- 12 Jun 2026+100.0%
Nothing announced by WINT that day or the session before.
- 9 Jun 2026+100.0%
Nothing announced by WINT that day or the session before.
- 3 Jun 2026+100.0%
Nothing announced by WINT that day or the session before.
Share of unusual movement by asset
For each asset, the share of WINT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 9% |
| Sessions with no dated event | — | 91% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
rostafuroxinNo recent activity | Phase 2 | Endogenous ouabain / mutant adducinSmall molecule | Hypertension Resistant Hypertension with Adducin/Ouabain Polymorphisms |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (13)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | — | $1.9M | $0.2M | $28M-$6.4M operating cash flow | report ↗ |
View 12 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q2 | — | $2.2M | $0.3M | $11M-$2.7M operating cash flow | report ↗ |
| 2025-Q1 | — | $2.3M | $1.2M | $4.0M-$2.4M operating cash flow | report ↗ |
| 2024-Q3 | — | $2.0M | $2.3M | $2.8M-$6.4M operating cash flow | report ↗ |
| 2024-Q2 | — | $9.9M | $1.8M | $12M-$2.3M operating cash flow | report ↗ |
| 2024-Q1 | — | $2.3M | $2.5M | —-$3.0M operating cash flow | report ↗ |
| 2023-Q3 | — | $2.1M | $7.4M | $4.4M-$3.9M operating cash flow | report ↗ |
| 2023-Q2 | — | $1.8M | $11M | $6.6M-$3.5M operating cash flow | report ↗ |
| 2023-Q1 | — | $1.4M | $4.2M | $4.1M-$2.5M operating cash flow | report ↗ |
| 2022-Q3 | — | $1.5M | $8.4M | $4.1M-$4.1M operating cash flow | report ↗ |
| 2022-Q2 | — | $3.0M | $11M | $17M-$5.3M operating cash flow | report ↗ |
| 2022-Q1 | — | $5.3M | $16M | $8.1M-$6.7M operating cash flow | report ↗ |
| 2021-Q3 | — | $4.7M | $25M | $8.2M-$5.3M operating cash flow | report ↗ |
Annual history (4 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $16M | $1.8M | $0.5M-$15M operating cash flow | report ↗ |
Windtree Therapeutics reported no revenue for fiscal 2024, with revenue not disclosed for the year. R&D spend was $16.28M, up 95.2% YoY from $8.34M. Cash and equivalents were $1.78M, and the company reported a net loss of $1.79M, with a quarterly net burn of $1.79M.
The 10-K highlights substantial doubt about the company’s ability to continue as a going concern and notes continued dependence on lead candidate istaroxime. Key disclosed events include a reverse stock split in April 2024, an asset purchase from Varian Biopharmaceuticals, license agreements involving Philip Morris aerosolization technology and Lees Pharmaceutical, and multiple financing transactions including convertible notes, senior secured notes, and private placement activity.
Insider transactions
Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2024-10-08 | Fraser Craig · director, President and CEO | Open-market purchase | 5,431 | $0.91 | $5K | Form 4 |
| 2024-07-22 | Fraser Craig · director, President and CEO | Award / grant (derivative) | 19 | — | — | Form 4 |
| 2024-07-22 | Simonson Steven · SVP, Chief Medical Officer | Award / grant (derivative) | 13 | — | — | Form 4 |
| 2024-07-22 | Fraser Craig · director, President and CEO | Award / grant (derivative) | 4,011 | — | — | Form 4 |
| 2024-07-22 | Simonson Steven · SVP, Chief Medical Officer | Award / grant (derivative) | 2,674 | — | — | Form 4 |
| 2023-09-27 | Fraser Craig · director, President and CEO | Open-market purchase | 2,500 | $1.02 | $3K | Form 4 |
| 2023-09-26 | Fraser Craig · director, President and CEO | Open-market purchase | 2,500 | $0.90 | $2K | Form 4 |
| 2023-08-23 | Geffken Daniel E. · director | Award / grant | 2,033 | — | — | Form 4 |